ISEE

IVERIC bio, Inc. (ISEE) | Rumor.io

IVERIC bio

ISEE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ISEE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 5

IVERIC bio, Inc.'s ($ISEE) IZERVAY has received FDA approval for the treatment of geographic atrophy, a type of vision loss.
The approval comes with a 12-month treatment limitation, which may impact competition with Apellis Pharmaceuticals' ($APLS) SYFOVRE, which has no such limitation.
Analysts are divided on the implications of the approval, with some viewing it as a positive for Apellis and others seeing it as a potential opportunity for IVERIC bio.

Generated by AI

Sentiment

Of the messages about ISEE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +11.55
Bearish	—	—	—	0% -11.55

Bullish· May 1

$ISEE has been a strong momentum stock, up 55% from its original buy point and considered an A+ momentum stock in the author's database.
The company has been acquired, with Astellas acquiring IVERIC bio, Inc., resulting in significant gains for long-term shareholders, with some gains reaching up to 187%.
The stock has shown consistent performance, with a 16% increase in value today and a 15% increase in premarket, and has been a well-managed company that has taken care of shareholders.

Bearish· Feb 17

The company's stock may decline to $15 next week due to its delayed NDA filing and being second to market after APLS.
The stock's recent price drop from $26 to $22 is significant, with some investors hoping it will tank to sub-$16 next week.
The stock has been a top loser in the market, declining by -5.39% and experiencing a 10.02% drop in the last 20 minutes, with high trading volumes.

Generated by AI

Topics

Of the messages about ISEE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	99.31%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0.69%

Analysts· Sep 7

Baird analyst Colleen Kusy maintains IVERIC bio with an Outperform rating and raises the price target from $27 to $34.
Guggenheim analyst Eddie Hickman maintains IVERIC bio with a Buy rating and raises the price target from $30 to $35.
Robert W. Baird increases IVERIC bio's price target to $34.00, maintaining an Outperform rating with +260% upside potential.

Announcements· May 1

Astellas Pharma is acquiring Iveric Bio (ISEE) for $40/share, totaling $5.9 billion.
The acquisition is expected to be completed in the third calendar quarter of 2023, subject to regulatory approvals.
The deal highlights Astellas' focus on revenue growth through strategic acquisitions, particularly in the ophthalmology sector.

Technical Analysis· Sep 6

Resistance levels for $ISEE are near $16.20 and $16.60 above $15.75, while support levels are near $14.40, $13.75, and previous levels below $15.
The stock has formed a double cup and handle pattern, which is a reliable indicator of a potential breakout, and is currently poised to break out of a bull flag.
Key levels to watch for $ISEE include $13.57, which is a support area, and $14.28, which is a previous high and potential resistance level.

Generated by AI

Community

Of the messages about ISEE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	97.78%	77.42%
Newcomers	—	—	2.22%	22.58%

Regulars· Jun 26

IVERIC bio, Inc.'s stock traded 219% above average volume, with a 2.02% increase in price.
IVERIC bio, Inc.'s Officer, SBLENDORIO GLENN, purchased shares valued at 146,486 USD on June 22.
IVERIC bio, Inc. is continuing to grow with innovative treatments in ophthalmic diseases, with a potential upside due to its promising treatments.

Newcomers· May 1

Astellas Pharma has agreed to acquire Iveric Bio for $40/share, a deal worth $5.9 billion.
Iveric Bio's stock has risen over 200% in less than a year, with newcomer investors citing the company's late-stage clinical bios and successful drug launches as key factors.
The acquisition is seen as a major bet on "second mover advantage" in the biotech sector, with analysts watching for further deals in the sector, particularly in ophthalmology.

Generated by AI

Also Discussed

Investors talking about ISEE also mention

#	Name	Attention
1	APLS - Apellis Pharmaceuticals, Inc.	——
2	DICE - DICE Therapeutics, Inc.	——
3	Pliant Therapeutics Inc.PLRX	0%0
4	YMAB - Y-mAbs Therapeutics, Inc.	——
5	AGRX - Agile Therapeutics, Inc.	——
6	Vaxcyte Inc.PCVX	0%0
7	Corvus Pharmaceuticals Inc.CRVS	0.01%-0.01
8	Vericel CorporationVCEL	0%0
9	ALPN - Alpine Immune Sciences, Inc.	——
10	AKRO - Akero Therapeutics, Inc.	——

IVERIC bio, Inc.

Location

Social

What share of all stock conversation is about ISEE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 5

IVERIC bio, Inc.'s ($ISEE) IZERVAY has received FDA approval for the treatment of geographic atrophy, a type of vision loss.
The approval comes with a 12-month treatment limitation, which may impact competition with Apellis Pharmaceuticals' ($APLS) SYFOVRE, which has no such limitation.
Analysts are divided on the implications of the approval, with some viewing it as a positive for Apellis and others seeing it as a potential opportunity for IVERIC bio.

Generated by AI

Sentiment

Of the messages about ISEE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +11.55
Bearish	—	—	—	0% -11.55

Bullish· May 1

$ISEE has been a strong momentum stock, up 55% from its original buy point and considered an A+ momentum stock in the author's database.
The company has been acquired, with Astellas acquiring IVERIC bio, Inc., resulting in significant gains for long-term shareholders, with some gains reaching up to 187%.
The stock has shown consistent performance, with a 16% increase in value today and a 15% increase in premarket, and has been a well-managed company that has taken care of shareholders.

Bearish· Feb 17

The company's stock may decline to $15 next week due to its delayed NDA filing and being second to market after APLS.
The stock's recent price drop from $26 to $22 is significant, with some investors hoping it will tank to sub-$16 next week.
The stock has been a top loser in the market, declining by -5.39% and experiencing a 10.02% drop in the last 20 minutes, with high trading volumes.

Generated by AI

Topics

Of the messages about ISEE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	99.31%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0.69%

Analysts· Sep 7

Baird analyst Colleen Kusy maintains IVERIC bio with an Outperform rating and raises the price target from $27 to $34.
Guggenheim analyst Eddie Hickman maintains IVERIC bio with a Buy rating and raises the price target from $30 to $35.
Robert W. Baird increases IVERIC bio's price target to $34.00, maintaining an Outperform rating with +260% upside potential.

Announcements· May 1

Astellas Pharma is acquiring Iveric Bio (ISEE) for $40/share, totaling $5.9 billion.
The acquisition is expected to be completed in the third calendar quarter of 2023, subject to regulatory approvals.
The deal highlights Astellas' focus on revenue growth through strategic acquisitions, particularly in the ophthalmology sector.

Technical Analysis· Sep 6

Resistance levels for $ISEE are near $16.20 and $16.60 above $15.75, while support levels are near $14.40, $13.75, and previous levels below $15.
The stock has formed a double cup and handle pattern, which is a reliable indicator of a potential breakout, and is currently poised to break out of a bull flag.
Key levels to watch for $ISEE include $13.57, which is a support area, and $14.28, which is a previous high and potential resistance level.

Generated by AI

Community

Of the messages about ISEE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	97.78%	77.42%
Newcomers	—	—	2.22%	22.58%

Regulars· Jun 26

IVERIC bio, Inc.'s stock traded 219% above average volume, with a 2.02% increase in price.
IVERIC bio, Inc.'s Officer, SBLENDORIO GLENN, purchased shares valued at 146,486 USD on June 22.
IVERIC bio, Inc. is continuing to grow with innovative treatments in ophthalmic diseases, with a potential upside due to its promising treatments.

Newcomers· May 1

Astellas Pharma has agreed to acquire Iveric Bio for $40/share, a deal worth $5.9 billion.
Iveric Bio's stock has risen over 200% in less than a year, with newcomer investors citing the company's late-stage clinical bios and successful drug launches as key factors.
The acquisition is seen as a major bet on "second mover advantage" in the biotech sector, with analysts watching for further deals in the sector, particularly in ophthalmology.

Generated by AI

IVERIC bio

Social

Aug 5

Sentiment

Bullish· May 1

Bearish· Feb 17

Topics

Analysts· Sep 7

Announcements· May 1

Technical Analysis· Sep 6

Community

Regulars· Jun 26

Newcomers· May 1

Also Discussed

IVERIC bio, Inc.

Company Information

Location

Also Discussed

Social

Aug 5

Sentiment

Bullish· May 1

Bearish· Feb 17

Topics

Analysts· Sep 7

Announcements· May 1

Technical Analysis· Sep 6

Community

Regulars· Jun 26

Newcomers· May 1